New Horizons in the Treatment and Management of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Expert Perspectives on Immunoglobulin Therapy

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive of the live session from the 2021 Spring Managed Care Forum.
If you participated in the live session, you are not eligible for
continuing education credits from this archive.

This activity is valid from June 1, 2021 – August 1, 2022
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
CSL Behring

Description:
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired immune-mediated inflammatory disorder of the peripheral nervous system. In CIDP, the myelin sheath, the protective covering of the nerves, is damaged. This may result in numbness or tingling, muscle weakness, fatigue, and other symptoms. CIDP effects can worsen over time, leading to significant activity limitations and a decreased quality of life. CIDP can occur at any age and is more common in men than in women. Approximately 30 percent of CIDP patients will progress to wheelchair dependence if not treated. In the U.S., it is estimated that the incidence of CIDP is up to two patients per 100,000 people each year, with a prevalence of 40,000 people affected. Despite available treatment options, many CIDP patients continue to struggle with daily disease and lifestyle challenges. Fortunately for these patients, novel immunoglobulin replacement therapies have recently become available that have shown improved efficacy and safety as a maintenance therapy in CIDP. With this new option comes a knowledge gap among physician medical directors, neurologists and nurse case managers as the treatment paradigm is growing.

First-line treatment for CIDP is currently intravenous immunoglobulin (IVIG) and other treatments include corticosteroids (e.g. prednisone), and plasmapheresis (plasma exchange) which may be prescribed alone or in combination with an immunosuppressant drug. However, recent controlled studies show how subcutaneous immunoglobin (SCIG), which has only recently become available for patients with CIDP, appears to be as effective for CIDP treatment as IVIG in most patients, and with fewer systemic side effects. Effective and timely treatment of CIDP can greatly improve the quality of life and outcomes in CIDP patients.

Upon completion of this activity, participants will be able to:

  • Review the pathophysiology and symptomatology of chronic inflammatory demyelinating polyneuropathy (CIDP) and its variants

  • Discuss the unmet needs and total cost of care for CIDP, including direct costs associated with drug therapy and associated infections from non-treatment, as well as indirect costs

  • Analyze the safety and efficacy of currently available and emerging immunoglobulin (Ig) replacement therapies for the management of CIDP and apply them to patient cases using evidence-based medicine

  • Compare and contrast the use of IVIG and SCIG in the management of CIDP

  • Employ shared decision-making when choosing treatment for patients with CIDP in the initial management and maintenance settings

  • Assess managed care considerations of Ig replacement therapies by exploring where these agents and their varying administration fit into current CIDP management paradigm

     

Faculty: Chafic Karam, MD
Neurologist
Penn Neuroscience Center
Perelman Center for Advanced Medicine

Disclosure:

Dr. Karam serves on as a consultant for Alnylam, Akcea, CSL Behring, Argenx, Biogen, and Genzyme. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no financial relationships with ineligible companies to disclose.
Jeremy Williams has no financial relationships with ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial relationships with ineligible companies to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
CSL Behring

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue